This alert
is to supplement previous communications issued:
Medicine
Supply Notification (MSN/2025/036) –
issued on 16th June 2025;
Medicine
Supply Notification (MSN/2025/036U) – issued on 14th August 2025; and
Medicine
Supply Notification (MSN/2025/036U2) – issued on 15th April 2026.
Levemir®
(insulin detemir) FlexPen® 100units/ml solution for injection 3ml
pre-filled pens and Levemir® (insulin detemir) Penfill®
100units/ml solution for injection 3ml cartridges are being discontinued from
end of December 2026 with stocks anticipated to be exhausted by this date.
Levemir® is a long-acting insulin
analogue with a prolonged duration of effect used as a basal insulin. It is
licensed for the treatment of diabetes mellitus in adults, adolescents and
children aged 1 year and above. It can be used alone as the basal insulin or in
combination with bolus insulin. It can also be used in combination with oral
antidiabetic medicinal products and/or GLP-1 receptor agonists.
A range of alternative insulins from other suppliers
are available. NOTE A
Please
refer to the SPS Medicines Supply Tool
entry for the discontinuation of Levemir® products
for an overview of the supply situation and up to date supply stock overview of
recommended insulins. The Medicines Supply Tool should be monitored regularly,
as supply capabilities of alternative options remain subject to change.
This National Patient Safety Alert provides further background, clinical information and actions for providers.